



MEDIA RELEASE

Medartis shareholders approve all proposals of the Board of Directors

- 84.8% of the total share capital was represented at this year's Annual General Meeting
- All proposals of the Board of Directors were approved with a large majority
- Ms. Nadia Tarolli Schmidt and Mr. Ciro Roemer were newly elected to the Board of Directors and all other persons standing for election were confirmed
- The company will use the profit from the 2021 financial year to accelerate its growth strategy and to finance capital expenditures

Basel, 6 April 2022: The shareholders of the Medartis Holding AG (SIX: MED) today approved all proposals of the Board of Directors with a clear majority of more than 91.7% of the votes and elected two new members to the highest governance body. Due to the high Corona case numbers, the AGM was not held as an attendance event.

Medartis' Annual General Meeting (AGM) was held without physical participation of shareholders due to the still high Corona case numbers. The persons holding shares were able to exercise their rights by giving written or electronic instructions to the independent proxy. In total, 10 013 719 shares or 84.8% of the total share capital were represented in this way.

The voters granted discharge to the members of the Board of Directors (BOD) for their activities in the 2021 business year. In two separate votes, the shareholders approved the maximum total compensation of the BOD from the AGM 2022 to the AGM 2023 and the maximum total compensation of the Executive Board (EMB) for the 2023 business year. In an advisory vote, the shareholders also approved the Compensation Report 2021.

Six of the previous eight members of the BOD were confirmed for a further one-year term of office with a large share of votes. Marco Gadola was re-elected Chairman of the BOD with 95.5% of the votes. In addition, Ms. Nadia Tarolli Schmidt and Ciro Römer were newly elected to the Board of Directors. Roland Hess and Dr. Jürg Greuter did not stand for re-election.

Increase of authorised and conditional share capital was approved

In accordance with its previous practice, the BOD proposed an extension and adjustment of the authorised and conditional share capital. The proposal of the BOD to increase the authorised share capital was approved with 91.7% of the votes. The BOD is therefore authorised to increase the share capital by a maximum amount of CHF 1 181 436.80 by issuing a maximum of 5 907 184 registered shares within the next two years. The increase of the conditional share capital by issuing up to 622 398 registered shares for employee participation plans was also approved with 94.4% of the votes.

In accordance with the proposal of the BOD, the shareholders confirmed the re-election of Ernst & Young AG as auditors. A detailed list of all resolutions and the voting distribution of the AGM 2022 is attached

and can be found under the following [link](#) on the Medartis website. The next AGM will take place on 21 April 2023 in Basel.

About Medartis

Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs approx. 650 individuals across its 14 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best-in-class service. For more information, please visit www.medartis.com.

Your contact:

Corporate Communications

Investor contact: investor.relations@medartis.com

Media contact: corporate.communication@medartis.com

+41 61 633 37 36

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.

#